

Yesim Ozguler

Country: Turkey

Contact e-mail: yesimozguler@yahoo.com

Year of birth: 1983

Mains diplomas:

- **MD:** 2007-Istanbul University, Cerrahpasa Medical Faculty, Turkey
- **Internal Medicine:** 2013- Istanbul University, Cerrahpasa Medical Faculty,Turkey
- **Rheumatologist:** Fellow since 2014- Istanbul University, Cerrahpasa Medical Faculty,Turkey

Current position and hospital/university:

Rheumatology fellow- Istanbul University, Cerrahpasa Medical Faculty,Turkey

Position within EULAR/international experience:

EMEUNET member since 2014

EMEUNET Working Group member since 2015

Fellow in the taskforce for the new EULAR recommendations for the management of Behçet's disease.

OMERACT fellow in Behçet's disease special interest group since 2014.

Role as EMEUNET working group member:

Member of the Peer Mentoring Subgroup

Areas of Research/Interest:

Behçet's disease

Vasculitis

Keywords: Behçet's disease, vasculitis, outcome measures

Select Publications:

Ozguler Y, Hatemi G, Yazici H. Management of Behçet's syndrome. Curr Opin Rheumatol. 2014;26(3):285-91

Borekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B, **Ozguler Y**, Musellim B, Hamuryudan V, Ongen G. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor- α treatment. Respiration. 2015;90(3):191-8

Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, **Ozguler Y**, Akman C, Tuzun H, Yurdakul S, Yazici H. Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45(3):369-73

Hatemi G, **Ozguler Y**, Direskeneli H, Mahr A, Gul A, Levi V, Aydin SZ, Mumcu G, Sertel-Berk O, Stevens RM, Yazici H, Merkel PA. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. J Rheumatol. 2015;42(12):2436-41.

Ozguler Y, Hatemi G. Management of Behçet's syndrome. Curr Opin Rheumatol. 2016;28(1):45-50.

Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, **Ozguler Y**, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksef F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A.Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor- α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. J Rheumatol. 2016;43(3):524-9.

Yazici H, **Ozguler Y**, Hatemi G, Yazici Y. Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. Arthritis Rheumatol. 2016;68(5):1315-6

Date of last update of the CV: September 2016